Synergistic approach to combating triple-negative breast cancer: ddr1-targeted antibody-drug conjugate combined with pembrolizumab

doi: 10.1016/j.jpha.2024.101100

• Shoubing Zhou^a,b , 
• Wenyu Li^a,b , 
• Dan Zhao^c , 
• Qiujun Zhang^a,b , 
• Hu Liu^{a,b ,  ,}  , 
• Tengchuan Jin^{c,d,e ,  ,}  , 
• Yueyin Pan^{a,b ,  ,} 

• a Department of Breast Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230031, China;

• b Department of Breast Oncology, Anhui Provincial Cancer Hospital, Hefei, 230031, China;

• c Laboratory of Structural Immunology, the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;

• d Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, University of Science and Technology of China, Hefei, 230001, China;

• e Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230027, China